PL366158A1 - Novel fibroblast growth factors - Google Patents

Novel fibroblast growth factors

Info

Publication number
PL366158A1
PL366158A1 PL01366158A PL36615801A PL366158A1 PL 366158 A1 PL366158 A1 PL 366158A1 PL 01366158 A PL01366158 A PL 01366158A PL 36615801 A PL36615801 A PL 36615801A PL 366158 A1 PL366158 A1 PL 366158A1
Authority
PL
Poland
Prior art keywords
growth factors
fibroblast growth
novel fibroblast
novel
factors
Prior art date
Application number
PL01366158A
Other languages
English (en)
Polish (pl)
Inventor
Peter W. Bringmann
Daryl Faulds
Bronislava Mitrovic
Subha Srinivasan
James Onuffer
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of PL366158A1 publication Critical patent/PL366158A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL01366158A 2000-12-08 2001-12-10 Novel fibroblast growth factors PL366158A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors
PCT/US2001/047350 WO2002046424A2 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Publications (1)

Publication Number Publication Date
PL366158A1 true PL366158A1 (en) 2005-01-24

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366158A PL366158A1 (en) 2000-12-08 2001-12-10 Novel fibroblast growth factors

Country Status (21)

Country Link
US (2) US20020151496A1 (cg-RX-API-DMAC7.html)
EP (1) EP1389237A2 (cg-RX-API-DMAC7.html)
JP (1) JP2005506275A (cg-RX-API-DMAC7.html)
KR (1) KR20040052442A (cg-RX-API-DMAC7.html)
CN (1) CN1518597A (cg-RX-API-DMAC7.html)
AU (1) AU2603402A (cg-RX-API-DMAC7.html)
BG (1) BG107888A (cg-RX-API-DMAC7.html)
BR (1) BR0116507A (cg-RX-API-DMAC7.html)
CA (1) CA2431374A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20031570A3 (cg-RX-API-DMAC7.html)
EE (1) EE200300269A (cg-RX-API-DMAC7.html)
HU (1) HUP0400657A1 (cg-RX-API-DMAC7.html)
IL (1) IL156259A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03005142A (cg-RX-API-DMAC7.html)
NO (1) NO20032573L (cg-RX-API-DMAC7.html)
PL (1) PL366158A1 (cg-RX-API-DMAC7.html)
RU (1) RU2329058C2 (cg-RX-API-DMAC7.html)
SI (1) SI21372A (cg-RX-API-DMAC7.html)
SK (1) SK7012003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002046424A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200305236B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
WO2003059270A2 (en) * 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
EP1608411B1 (en) * 2003-04-01 2010-09-29 United States Government as represented by the Department of Veteran's Affaires Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure.
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
LT2726511T (lt) 2011-07-01 2019-11-11 Ngm Biopharmaceuticals Inc Kompozicijos, panaudojimai ir būdai, skirti metabolinių sutrikimų ir ligų gydymui
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
AU2013370404B2 (en) 2012-12-27 2017-11-02 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX377380B (es) 2013-10-28 2025-03-10 Ngm Biopharmaceuticals Inc Modelos de cáncer y métodos asociados.
SI3097122T1 (sl) 2014-01-24 2020-07-31 Ngm Biopharmaceuticals, Inc. Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
UA123763C2 (uk) 2014-10-23 2021-06-02 Енджіем Байофармасьютикалз, Інк. Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
JP2003512841A (ja) * 1999-10-22 2003-04-08 カイロン コーポレイション ヒトおよびラットｆｇｆ−２０遺伝子および遺伝子発現産物
JP2003516731A (ja) * 1999-11-18 2003-05-20 カイロン コーポレイション ヒトｆｇｆ−２１遺伝子および遺伝子発現産物
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
WO2002002625A2 (en) * 2000-07-03 2002-01-10 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same

Also Published As

Publication number Publication date
JP2005506275A (ja) 2005-03-03
CA2431374A1 (en) 2002-06-13
HUP0400657A1 (en) 2006-04-28
US20080057076A1 (en) 2008-03-06
ZA200305236B (en) 2005-06-29
SI21372A (sl) 2004-06-30
EP1389237A2 (en) 2004-02-18
RU2003119657A (ru) 2005-02-27
AU2002226034A2 (en) 2002-06-18
IL156259A0 (en) 2004-01-04
BR0116507A (pt) 2004-01-06
NO20032573D0 (no) 2003-06-06
RU2329058C2 (ru) 2008-07-20
CN1518597A (zh) 2004-08-04
CZ20031570A3 (cs) 2004-01-14
KR20040052442A (ko) 2004-06-23
BG107888A (bg) 2004-08-31
AU2603402A (en) 2002-06-18
US20020151496A1 (en) 2002-10-17
NO20032573L (no) 2003-07-22
WO2002046424A3 (en) 2003-11-27
EE200300269A (et) 2003-10-15
MXPA03005142A (es) 2004-10-15
SK7012003A3 (en) 2004-04-06
WO2002046424A2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
IL156259A0 (en) Novel fibroblast growth factors
IL150544A0 (en) Novel biarylcarboxamides
CA95984S (en) Pantiliner
AU8860401A (en) Novel guanidinobenzamides
AU3924300A (en) Fibroblast growth factor-20
AU1217102A (en) Novel arylalkane-sulfonamides
IL153471A0 (en) Novel arylethene-sulfonamides
GB2414798B (en) Fibroblast growth factor binding assay
GB0007451D0 (en) Tableware
GB0022992D0 (en) Novel vompounds
CA90931S (en) Pantiliner
GB0013272D0 (en) Neurotropic growth factor
AU9149301A (en) Growth factor complex
GB0000829D0 (en) Growth inhibitor
GB0019524D0 (en) Novel use
TW418600U (en) Convex flowerpot
CA90930S (en) Pantiliner
PL110774U1 (en) Flowerpot
TW425839U (en) Flowerpot
GB0005769D0 (en) Pot
CA86570S (en) Greenhouse
EG22115A (en) Greenhouse
SI1259508T1 (en) Novel biarylcarboxamides
GB0031462D0 (en) Culturing tissue
GB0031651D0 (en) Culturing tissue

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)